Category: Muscular dystrophy

Deflazacort (Emflaza), a corticosteroid, was the first steroid to receive FDA approval specifically for the treatment of Duchenne muscular dystrophy (DMD). It is prescribed for adults and children two years of age and older to help preserve muscle function and strength.

According to clinical studies, Defzorix 6 Suspension, which contains the corticosteroid Deflazacort, helps to significantly improve muscle strength and delay disease progression in patients with Duchenne muscular dystrophy (DMD). Beyond DMD, this medication is also prescribed for a range of other inflammatory and autoimmune conditions where its potent immunosuppressive effects are needed.

In October 2023, the U.S. Food and Drug Administration (FDA) approved vamorolone (brand name Agamree) for the treatment of Duchenne muscular dystrophy (DMD), signaling a new approach in steroid therapy. This first-in-class drug is a novel dissociative corticosteroid, designed to retain the therapeutic benefits of traditional steroids while minimizing common adverse side effects.